Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Al-Kuraishy, Hayder M; Al-Gareeb, Ali I; Waheed, Huda Jaber

doi:10.4103/jnrp.jnrp_97_18

Cited by 26 publications

(18 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be because human Lp-PLA2 is highly glycosylated, which makes it difficult for Lp-PLA2 to bind to HDL-C. And under physiological conditions, Lp-PLA2 is mainly attached to LDL in the circulation. Alkuraishy et al [ 28 ] also reported that in patients with cerebral stroke, Lp-PLA2 mass levels were positively correlated with very low-density lipoprotein. In our previous study, we found that the level of Lp-PLA2 in gestational diabetic rats induced by streptozocin was significantly up-regulated.…”

Section: Discussionmentioning

confidence: 99%

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance

et al. 2021

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is one of the most common complications of pregnancy and associated with adverse pregnancy outcomes. The aim of this study was to investigate the changes of lipoprotein-associated phospholipaseA2 (Lp-PLA2) level and its correlation with biochemical indexes in patients with GDM.This observational cross-sectional study was performed among 52 GDM and 48 healthy pregnant women. Automatic biochemical analyzer was employed to test the biochemical indexes, including fasting plasma glucose (FPG), Hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). The lipoprotein-associated phospholipaseA2 (Lp-PLA2) level was evaluated by enzyme-linked immunosorbent assay, and homeostatic model assessment for insulin resistance (HOMA-IR) was calculated.The levels of FPG, HbA1c, HOMA-IR, TG, TC and LDL-C were significantly increased while high-density lipoprotein cholesterol (HDL-C) level was significantly decreased in the GDM group when compared with those in the control group. Lp-PLA2 level in maternal blood in the GDM group was significantly higher than that in the control group (199.125 ± 23.494 vs165.825 ± 15.576 ng/ mL, P < .05) and logistic regression analysis further confirmed the association of Lp-PLA2 levels with GDM. Furthermore, Lp-PLA2 positively correlated with HOMA-IR, TC, and LDL-C.Our results confirmed the association of Lp-PLA2 with GDM. This broadens our knowledge on the pathophysiology of GDM and provides insights into the development of new targets for the prevention and treatment of GDM.Abbreviations: CI = confidence interval, FPG = fasting plasma glucose, GDM = gestational diabetes mellitus, HbA1c = hemoglobin A1c, HDL = high-density lipoprotein, HDL-C = high-density lipoprotein cholesterol, HOMA-IR = homeostatic model assessment for insulin resistance, IR = insulin resistance, LDL = low-density lipoprotein, LDL-C = low-density lipoprotein cholesterol, Lp-PLA2 = lipoprotein-associated phospholipaseA2, OR = odds ratios, TC = total cholesterol, TG = triglyceride.

show abstract

Section: Discussionmentioning

confidence: 99%

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, it is also known as platelet‐activating factor acetylhydrolase (PAF‐AH) (Dennis, Cao, Hsu, Magrioti, & Kokotos, ; Zhou et al, ). In recent years, its application in atherosclerosis‐associated cardiovascular and cerebrovascular diseases has attracted extensive attention (Alkuraishy, Al‐Gareeb, & Waheed, ; Esenwa & Elkind, ; Gorelick, ). Many early studies have considered that (Elkind, Tai, Coates, Paik, & Sacco, ; Lp‐PLA(2) Studies Collaboration et al, ; Oei et al, ) Lp‐PLA2 can hydrolyze platelet‐activating factors, inhibit thrombosis and alleviate inflammation, and work against atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

“…Many early studies have considered that (Elkind, Tai, Coates, Paik, & Sacco, ; Lp‐PLA(2) Studies Collaboration et al, ; Oei et al, ) Lp‐PLA2 can hydrolyze platelet‐activating factors, inhibit thrombosis and alleviate inflammation, and work against atherosclerosis. At present, it has been considered that (Alkuraishy et al, ; Yang et al, ) some kinds of Lp‐PLA2 that can bind with high density lipoprotein (HDL) can hydrolyze oxidized phospholipids in blood, reduce the accumulation of inflammatory mediators in phagocytes, and inhibit foam cell formation, thereby exerting anti‐inflammatory and anti‐atherosclerotic effects. In the process of the hydrolysis of oxidized low‐density lipoprotein (ox‐LDL), sLp‐PLA2 produces oxidized free fatty acids (ox‐FFA) and lysolecithin (lyso‐PC) (Bonnefont‐Rousselot, ; Ulrich et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, its application in atherosclerosis-associated cardiovascular and cerebrovascular diseases has attracted extensive attention (Alkuraishy, Al-Gareeb, & Waheed, 2018;Esenwa & Elkind, 2016;Gorelick, 2008). Many early studies have considered that (Elkind, Tai, Coates, Paik, & Sacco, 2006 which promote plaque rupture and cause more Lp-PLA2 to be released into circulation (Ye et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of dl‐3‐n‐butylphthalide on serum lipoprotein‐associated phospholipase A2 and hypersensitive C‐reactive protein levels in acute cerebral infarction

Zhang¹,

Dong²,

Liu³

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

ObjectiveThis study aims to explore the curative effect of dl‐3‐n‐butylphthalide (NBP) on patients with acute cerebral infarction (ACI) and its effects on serum lipoprotein‐associated phospholipase A2 (Lp‐PLA2) and hypersensitive C‐reactive protein (hs‐CRP) levels.MethodsA total of 136 ACI patients treated in our hospital, who met the criteria, were selected and randomly divided into two groups: control group (n = 60, including 28 males and 32 females) and treatment group (n = 76, including 32 males and 44 females). Patients in the control group were treated with routine drug therapy, while patients in the treatment group were treated with NBP on this basis. A dose of 100 ml was administered by intravenous injection for 2 times/day, for 14 days. The curative effect was evaluated using the National Institute of Health Stroke Scale (NIHSS) and Barthel index (BI) self‐care ability. The levels of the two factors in serum were measured using enzyme‐linked immunosorbent assay, and the changes in levels of these two factors in serum at different time points before and after treatment were compared between the two groups.Results(a) Lp‐PLA2 and hs‐CRP levels in the treatment group after treatment were significantly lower than those before treatment and those in the control group after treatment (p < .05). (b) The NIHSS and BI scores in the treatment group were significantly lower after treatment than before treatment and those in the control group after treatment (p < .05).ConclusionDl‐3‐n‐butylphthalide can improve the expression of Lp‐PLA2 and hs‐CRP in serum in ACI patients. Furthermore, NBP has significant efficacy in inhibiting inflammation and improving neurological symptoms.

show abstract

“…Besides, results of the present study revealed that rosuvastatin improved insulin sensitivity in a dose-dependent manner as 40 mg/kg rosuvastatin led to the improvement of IR with reduction in the insulin release due to the inhibition of gluconeogenesis through the modulation of peroxisome proliferative-activated receptor-γ coactivator-1 (PGC-1α) pathway. [2728]…”

Section: Discussionmentioning

confidence: 99%

Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect

Al-Kuraishy

Al-Gareeb

2019

J Adv Pharm Technol Res

View full text Add to dashboard Cite

Obesity refers to an excess of body fat content causing metabolic and inflammatory disorders. Therefore, the aim of the present study was to investigate dose-dependent effect of rosuvastatin on the metabolic profile of diet-induced obesity in mice model study. A total number of 40 male Albino Swiss mice were used which divided into Group I: Control group, fed normal diet for 8 weeks ( n = 10); Group II: High-fat diet (HFD) group, fed on HFD for 8 weeks ( n = 10); Group III: HFD + 20 mg/kg rosuvastatin for 8 weeks ( n = 10); and Group IV: HFD +40 mg/kg rosuvastatin for 8 weeks ( n = 10). Anthropometric and biochemical parameters were estimated, including fasting blood glucose, lipid profile, fasting insulin, and glucose tolerance test (GTT). Mice on HFD fed showed a significant increase in the insulin resistance, body weight, deterioration of lipid profile and significant reduction in the β-cell function, and insulin sensitivity compared to the control P < 0.05. GTT and blood glucose level were significantly high in HFD fed group compared to the control group P < 0.05. Rosuvastatin in a dose of 40 mg/kg illustrated better effect than 20 mg/kg on the glucometabolic profile P < 0.05. Rosuvastatin may has a potential effect on reduction of glucometabolic changes induced by HFD with significant amelioration of pancreatic β-cell function in dose-dependent manner.

show abstract

Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins

Cited by 26 publications

References 52 publications

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance

Effects of dl‐3‐n‐butylphthalide on serum lipoprotein‐associated phospholipase A2 and hypersensitive C‐reactive protein levels in acute cerebral infarction

Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect

Contact Info

Product

Resources

About